Details of the Drug Combinations

General Information of This Drug (ID: DMAS1RB)

Drug Name

MK-8776 DMAS1RB

Synonyms

MK-8776 Racemate; MK-8776 S-isomer; SCH900776 (Racemate); CHEMBL1643208; 6-bromo-3-(1-methyl-1H-pyrazol-4-yl)-5-(piperidin-3-yl)pyrazolo[1,5-a]pyrimidin-7-amine; 6-bromo-3-(1-methylpyrazol-4-yl)-5-piperidin-3-ylpyrazolo[1,5-a]pyrimidin-7-amine; 891495-88-8; SCH900776 S-isomer; GTPL7943; SCHEMBL10380123; CHEBI:131165; HMS3656J19; 6-BROMO-3-(1-METHYLPYRAZOL-4-YL)-5-[(3R)-PIPERIDIN-3-YL]PYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE; BCP02883; BDBM50334854; NSC764659; AKOS026750519; MK 8776; NSC-764659; NCGC00387868-02; DA-40779; BCP0726000317; FT-0700501; FT-0771683; J3.517.083I; Q27086899; SCH 900776 (CAS:891494-64-7); 6-bromo-3-(1-methylpyrazol-4-yl)-5-[(3S)-piperidin-3-yl]pyrazolo[1,5-a]pyrimidin-7-amine; 6-bromo-3-(1-methylpyrazol-4-yl)-5-piperidin-3-ylpyrazolo[5,1-b]pyrimidin-7-amine

Indication

Disease Entry	ICD 11	Status	REF
Hodgkin lymphoma	2B30	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Gemcitabine + MK-8776	DCA7QCM	Gemcitabine	Hodgkin Disease	[1]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00779584) A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248). U.S. National Institutes of Health.